Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
(NASDAQ: MDCX) Delayed: 0.46 +0.01 (2.22%)
Previous Close $0.45    52 Week High $ 
Open $0.43    52 Week Low $ 
Day High $0.47    P/E N/A 
Day Low $0.43    EPS $ 
Volume 1,375,470       

(NASDAQ: MDCX) Delayed: 0.46 +0.01 (2.22%)
Previous Close $0.45    52 Week High $ 
Open $0.43    52 Week Low $ 
Day High $0.47    P/E N/A 
Day Low $0.43    EPS $ 
Volume 1,375,470